Go to main content

Press Releases

Explore the archived press releases about AOP Health, its products, studies and cooperations. We will be happy to answer any questions or comments you may have via aop-health@aoporphan.com 

AOP Orphan Pharmaceuticals presents latest analysis on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia vera at the prestigious American Society of Hematology (ASH) 2021 Annual Meeting

14. 12. 2021

BESREMi® (Ropeginterferon alfa-2b) approved by the US FDA

15. 11. 2021

New Approaches for Fostering Rare Disease Research

18. 10. 2021

Can European Solutions Allow Equal Access to Rare Disease Drugs in All European Countries?

6. 10. 2021

Austrian AOP Orphan to Tap into U.S. Market with Partner Eagle Pharmaceuticals

28. 9. 2021

AOP Orphan Announces Leadership Changes to Advance Long Term Strategic Direction

27. 8. 2021